Diana Miller
Family Medicine · Oceanside, CANPI 1407204969
Payments from drug & device makers
Across 493 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$3K
- Johnson & Johnson$1K
- Janssen Products, LP$414
- Lilly USA, LLC$137
- Theratechnologies Inc.$99
- plus $498 from 14 others
What the payments were for
- Travel & lodging$330%
- Food & beverage$9,54997%
- Education$2953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 182 | $4,477 |
| Gilead | 193 | $3,127 |
| Johnson & Johnson | 78 | $1,126 |
| Janssen Products, LP | 5 | $414 |
| Lilly USA, LLC | 6 | $137 |
| Theratechnologies Inc. | 4 | $99 |
| AbbVie | 4 | $97 |
| Hologic Sales And Service, LLC | 3 | $62 |
| Merck | 3 | $58 |
| EMD Serono, Inc. | 3 | $53 |
| Novo Nordisk | 2 | $46 |
| Bayer | 2 | $36 |
| Exact Sciences | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,877 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 154 | $576,779 |
| JulucaDolutegravir/Rilpivirine | 46 | $161,239 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $96,189 |
| PrezcobixDarunavir/Cobicistat | 29 | $75,216 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $67,945 |
| TivicayDolutegravir Sodium | 25 | $61,524 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $59,696 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $54,608 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $43,636 |
| OzempicSemaglutide | 21 | $28,775 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $17,379 |
| TrulicityDulaglutide | 16 | $15,718 |
| JardianceEmpagliflozin | 16 | $12,924 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $10,792 |
| JanuviaSitagliptin Phosphate | 11 | $10,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,127 | $644,724184 claims |
| Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Dovato | $4,477 | $326,095100 claims |
| Janssen Products, LPSymtuza | $414 | $96,18922 claims |
| Johnson & JohnsonPrezcobix | $1,126 | $75,21629 claims |
| MerckJanumet, Januvia, Dulera | $58 | $31,90935 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $18 | $30,18643 claims |
| Novo NordiskOzempic | $46 | $28,77521 claims |
| Lilly USA, LLCTrulicity | $137 | $15,71816 claims |
| GSKIncruse Ellipta | $20 | $4,76815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Oceanside
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.